Confo Therapeutics is awarded a € 1 million grant to increase its screening capabilities
Ghent, Belgium: 20 February 2018 - Confo Therapeutics announced today that it has received a € 1 million grant from the Flemish Government through Flanders Innovation & Entrepreneurship (VLAIO). The grant will be used to support the development of new methods for screening libraries of small molecules for the discovery of new therapeutic candidates targeting G-protein coupled receptors (GPCRs), using the company's proprietary conformation-sensitive single domain antibodies or Confobodies.
More info on Confo Therapeutics' website
Next > NGDATA named 2017 Tech Trailblazer for Big Data
Previous > Mainstay Medical announces € 30 million financing new capital to complete US Pivotal ReActiv8-B clinical study and advance european commercialization